Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Study of TR-701 in Patients With Complicated Skin and Skin Structure Infections

Role: lead

Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg

Role: lead

Microdialysis and Pharmacokinetic Study of TR-701

Role: lead

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

Role: lead

Pharmacokinetic (PK) Study of Oral and IV TR-701 FA in Adolescent Patients

Role: lead

A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects

Role: lead

TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.

Role: lead

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

Role: lead

TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Role: lead

A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response

Role: lead

Food Effects of Single Oral Dose of 600mg TR-701

Role: lead

A Phase 1, Open-Label, 10 Day Safety Study

Role: lead

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

Role: lead

Single and Multiple Ascending Dose Pharmacokinetic Study of TR701 in Healthy Adults

Role: lead

A PK and Safety Study in Subjects With Hepatic Impairment

Role: lead

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

Role: lead

Exploratory Pharmacokinetic and Bioavailability Study of 2 Capsule Formulations of Torezolid Phosphate

Role: lead

A Phase 1 TR-701 FA Study of Blood Pressure Response Post Tyramine Challenge

Role: lead

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

Role: lead